Current management and novel agents for malignant melanoma

Advanced malignant melanoma remains a challenging cancer. Over the past year, there have been 3 agents approved for treatment of melanoma by Food and Drug Administration. These include pegylated interferon alpha-2b for stage III melanoma, vemurafenib for unresectable or metastatic melanoma with BRAF...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Byung, Mukhi, Nikhil, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3293076/
https://www.ncbi.nlm.nih.gov/pubmed/22333219
http://dx.doi.org/10.1186/1756-8722-5-3
_version_ 1782225366906044416
author Lee, Byung
Mukhi, Nikhil
Liu, Delong
author_facet Lee, Byung
Mukhi, Nikhil
Liu, Delong
author_sort Lee, Byung
collection PubMed
description Advanced malignant melanoma remains a challenging cancer. Over the past year, there have been 3 agents approved for treatment of melanoma by Food and Drug Administration. These include pegylated interferon alpha-2b for stage III melanoma, vemurafenib for unresectable or metastatic melanoma with BRAF V600E mutation, and ipilimumab for treatment of unresectable or metastatic melanoma. This review will also update on the development of novel agents, including tyrosine kinase inhibitors and adoptive cellular therapy.
format Online
Article
Text
id pubmed-3293076
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32930762012-03-05 Current management and novel agents for malignant melanoma Lee, Byung Mukhi, Nikhil Liu, Delong J Hematol Oncol Review Advanced malignant melanoma remains a challenging cancer. Over the past year, there have been 3 agents approved for treatment of melanoma by Food and Drug Administration. These include pegylated interferon alpha-2b for stage III melanoma, vemurafenib for unresectable or metastatic melanoma with BRAF V600E mutation, and ipilimumab for treatment of unresectable or metastatic melanoma. This review will also update on the development of novel agents, including tyrosine kinase inhibitors and adoptive cellular therapy. BioMed Central 2012-02-14 /pmc/articles/PMC3293076/ /pubmed/22333219 http://dx.doi.org/10.1186/1756-8722-5-3 Text en Copyright ©2012 Lee et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Lee, Byung
Mukhi, Nikhil
Liu, Delong
Current management and novel agents for malignant melanoma
title Current management and novel agents for malignant melanoma
title_full Current management and novel agents for malignant melanoma
title_fullStr Current management and novel agents for malignant melanoma
title_full_unstemmed Current management and novel agents for malignant melanoma
title_short Current management and novel agents for malignant melanoma
title_sort current management and novel agents for malignant melanoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3293076/
https://www.ncbi.nlm.nih.gov/pubmed/22333219
http://dx.doi.org/10.1186/1756-8722-5-3
work_keys_str_mv AT leebyung currentmanagementandnovelagentsformalignantmelanoma
AT mukhinikhil currentmanagementandnovelagentsformalignantmelanoma
AT liudelong currentmanagementandnovelagentsformalignantmelanoma

Ejemplares similares